Simlukafusp alfa (FAP-IL2v) is an immunocytokine designed for targeted immunotherapy; it binds to fibroblast activation protein alpha (FAPα) on stromal cells in the tumor microenvironment and delivers an IL-2 variant that selectively engages the IL-2 receptor βγ subunits (IL-2Rβγ), thereby stimulating anti-tumor immune responses while minimizing activation of immunosuppressive regulatory T cells.